Bosutinib for Successful Treatment‐Free Remission in Chronic Myeloid Leukemia
Cancer Medicine · 2025-05 · 14 (9)
DOI: 10.1002/cam4.70822 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 28.04.2025. Verfasst von Yuki Fujioka und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan. Hauptthemen laut MEDLINE: Aniline Compounds, Nitriles, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Quinolines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction and Objective This study explored the status of patients with chronic myeloid leukemia following the safe discontinuation of frontline or second‐line bosutinib treatment. The goal was to assess the long‐term outcomes and factors influencing treatment‐free remission (TFR) following cessation of bosutinib therapy.
Methods
The median duration of bosutinib treatment among 16 patients was 48 months. All patients achieved a deep molecular response before bosutinib discontinuation, which was sustained for a median pre‐cessation period of 27 months. Patients were monitored for molecular response and clinical outcomes.
Results
After bosutinib discontinuation, the major molecular response was lost in six patients: within 6 months in five patients and at 19 months in one patient. All six patients achieved a major molecular response after at least 3 months of bosutinib re‐treatment. Ten patients exhibited successful TFR without loss of major molecular response for a median duration of 48 (16–101) months. Kaplan–Meier analysis revealed a 68.8% treatment‐free survival at 12 months. After bosutinib cessation, eight patients developed Grade 1–2 withdrawal syndrome. No differences were observed in the clinical characteristics or bosutinib treatment between patients with TFR at 12 months (TFR group) and those without remission (recurrence group), except for the deep molecular response duration before bosutinib cessation (31 vs. 24 months, p = 0.009). T‐cell profiling using flow cytometry revealed a higher percentage of effector memory CD8 + T cells at 1 and 3 months after bosutinib discontinuation in the TFR group than in the recurrence group ( p = 0.012 and p = 0.005, respectively).
Conclusion
Bosutinib can be safely discontinued under certain conditions, similar to other tyrosine kinase inhibitors. Additionally, T‐cell profile analysis before and after bosutinib discontinuation may predict successful TFR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan.
- Division of Central Laboratory, Akita University Hospital, Akita, Japan.
- Department of Pharmacy, Akita University Hospital, Akita, Japan.
- Division of Transfusion and Cell Therapy, Hamamatsu University Hospital, Hamamatsu, Japan.
ORCID-Profile: Yuki Fujioka, Naoto Takahashi
Zitieren
APA
Fujioka, Y., Abumiya, M., Ono, T., & Takahashi, N. (2025). Bosutinib for Successful Treatment‐Free Remission in Chronic Myeloid Leukemia. Cancer Medicine, 14(9). https://doi.org/10.1002/cam4.70822
Vancouver
Fujioka Y, Abumiya M, Ono T, Takahashi N. Bosutinib for Successful Treatment‐Free Remission in Chronic Myeloid Leukemia. Cancer Medicine. 2025;14(9). doi:10.1002/cam4.70822
BibTeX
@article{Fujioka2025,
author = {Fujioka, Yuki and Abumiya, Maiko and Ono, Takaaki and Takahashi, Naoto},
title = {Bosutinib for Successful Treatment‐Free Remission in Chronic Myeloid Leukemia},
journal = {Cancer Medicine},
year = {2025},
volume = {14},
number = {9},
doi = {10.1002/cam4.70822}
}
EUVIMED